Log in

NASDAQ:SVA - Sinovac Biotech Stock Price, Forecast & News

0.00 (0.00 %)
(As of 04/8/2019)
Today's Range
Now: $6.47
50-Day Range
MA: $6.47
52-Week Range
Now: $6.47
Average VolumeN/A
Market Capitalization$460.28 million
P/E RatioN/A
Dividend YieldN/A
Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SVA



Sales & Book Value

Annual Sales$229.65 million
Cash Flow$0.46 per share
Book Value$5.10 per share



Market Cap$460.28 million
Next Earnings Date4/22/2020 (Estimated)

Receive SVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions

What is Sinovac Biotech's stock symbol?

Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."

How were Sinovac Biotech's earnings last quarter?

Sinovac Biotech Ltd. (NASDAQ:SVA) released its quarterly earnings data on Friday, November, 15th. The biopharmaceutical company reported $0.07 earnings per share for the quarter. The biopharmaceutical company earned $64.34 million during the quarter. View Sinovac Biotech's Earnings History.

When is Sinovac Biotech's next earnings date?

Sinovac Biotech is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Sinovac Biotech.

Has Sinovac Biotech been receiving favorable news coverage?

Media stories about SVA stock have trended positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sinovac Biotech earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Sinovac Biotech.

Who are some of Sinovac Biotech's key competitors?

What other stocks do shareholders of Sinovac Biotech own?

Who are Sinovac Biotech's key executives?

Sinovac Biotech's management team includes the folowing people:
  • Wei Dong Yin, Chairman, President, CEO & Secretary
  • Nan Wang, Chief Financial Officer & VP-Business Development
  • Qiang Gao, Vice President-Research & Development
  • Xiao Mei Yin, Vice President-Sales & Marketing
  • Helen G. Yang, Investor Relations Contact

How do I buy shares of Sinovac Biotech?

Shares of SVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sinovac Biotech's stock price today?

One share of SVA stock can currently be purchased for approximately $6.47.

How big of a company is Sinovac Biotech?

Sinovac Biotech has a market capitalization of $460.28 million and generates $229.65 million in revenue each year. Sinovac Biotech employs 735,644 workers across the globe.View Additional Information About Sinovac Biotech.

What is Sinovac Biotech's official website?

The official website for Sinovac Biotech is http://www.sinovac.com/.

How can I contact Sinovac Biotech?

Sinovac Biotech's mailing address is 39 SHANGDI XI ROAD HAIDIAN DISTRICT, BEIJING F4, 100085. The biopharmaceutical company can be reached via phone at 86-10-8289-0088 or via email at [email protected]

MarketBeat Community Rating for Sinovac Biotech (NASDAQ SVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  459
MarketBeat's community ratings are surveys of what our community members think about Sinovac Biotech and other stocks. Vote "Outperform" if you believe SVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel